Drug Discovery
One of the key aims of the Beatson Institute is to translate our basic research for patient benefit and we are working towards this goal in two main areas; drug discovery based on biological pathways under investigation in the basic science programmes and links with clinical trials through our clinical colleagues.

Funded by an initial five-year grant from Cancer Research UK and headed by Martin Drysdale, our goal is to establish an integrated, industry-standard drug discovery programme to translate basic biology research from the Beatson and other CR-UK centres into medicines for the treatment of cancer.

The Drug Discovery Programme (DDP) at the Beatson will establish expertise in Fragment-Based Drug Discovery (FBDD) within the Structural Biology group, integrated alongside Chemistry and Biology. State-of-the-art 600MHz NMR with cryo-cooling will be used in conjunction with Surface Plasmon Resonance (SPR) as our primary fragment screening technologies, backed up by X-ray crystallography.

We are currently looking to recruit key individuals to help develop and drive the DDP forward. See our Recruitment pages for details.

icon DDP Scientific Report 2010 (179.89 kB)

For more details, see CR-UK and BBC News, 22nd September 2009
 
[ Back ]